Taysha Gene Therapies (TSHA) PT Raised to $10 at BMO Capital

May 7, 2026 7:46 AM

BMO Capital analyst Evan Seigerman raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $10.00 (from $8.00) while maintaining a Outperform rating.

No results found